Alexandria Real Estate Equities

▲ Bull Case

• ◆Cambridge cluster fills first. Kendall Square's network effects (MIT, Harvard, Broad Institute proximity) make ARE's Cambridge portfolio the first to lease up in any biotech recovery. If Cambridge occupancy returns to 92-94% by FY2028, it alone generates $100-120M incremental NOI and validates the PWFV thesis.
• ◆AI drug discovery increases wet lab demand. In silico drug screening doesn't replace wet labs — it multiplies them. AI generates 10x more drug targets per dollar of R&D spend, each requiring physical validation. GLP-1 follow-ons, oncology, and AI-assisted drug discovery create sustained 5-10 year demand cycle centered on ARE's megacampus locations.
• ◆$2.9B disposition + NAV unlock. Successful completion of the disposition program drives Net Debt/EBITDA from 6.4x → 5.5x, eliminates credit downgrade risk, and signals to the market that NAV is real and monetizable — catalyzing multiple re-rating from 7x to 14-16x FFO on recovering earnings.

▼ Bear Case

• ◆Lab market fundamentally broken; recovery timeline extends to 2029. Management itself used the phrase 'fundamentally broken' on Q4 2025 earnings. If 1.2M SF of 2026 lease expirations are absorbed only through heavy free rent and TI concessions, cash NOI recovery is later than headline leasing metrics suggest.
• ◆Second dividend cut in FY2027. At 73% FFO payout ratio, a single occupancy miss pushes payout toward 80%+; management cuts dividend to preserve capital for development and deleveraging; yield-sensitive holders exit; multiple stays depressed at 8-9x AFFO through FY2028.
• ◆Disposition program executes at distressed prices. Buyers demand 8-9%+ cap rates on non-core ARE assets; $2.9B target achieves only $1.5-2.0B; leverage stays above 6x; credit agencies place ARE on negative watch; financing costs rise on refinancing.

“Bull consensus: ARE is a temporarily impaired high-quality REIT with irreplaceable cluster assets, fortress balance sheet ($4.2B liquidity, 10-yr debt maturity), and 7x trough FFO pricing; the lab oversupply is cyclical, identical in structure to 2009-2012 REIT downturns, and will recover over 2-3 years as biotech VC normalizes and new supply is paused. At $45 and 10.4% yield, the risk/reward is compelling. Bear consensus: The FY2025 $1.45B impairment charge signals permanent asset value destruction; ARE management acknowledged the market is 'fundamentally broken' and multi-year recovery is the base case; free rent and elevated TIs mean headline leasing metrics overstate cash NOI recovery; AI/in silico drug discovery may structurally reduce wet lab demand over the next decade. The decisive question: Will Q2-Q3 2026 leasing velocity (in SF/quarter) show an inflection from Q1 2026's depressed 647K SF? A rebound to 900-1,000K SF/quarter in mid-2026 confirms the cyclical recovery thesis; another sub-700K SF quarter confirms the extended bear case.”

• ◆Q2-Q3 2026 leasing volume rebounds to 900K+ SF/quarter (Q3-Q4 2026) — confirms cyclical thesis; +20-30%
• ◆$1.0B+ disposition executed at 6-7% cap rate (H1 2026) — de-risks leverage narrative; +10-15%
• ◆NIH budget finalized without major cut (H2 2026) — academic tenant demand stabilizes; +5-10%
• ◆Q4 2026 occupancy guidance raised above 88.5% (Q3 2026 earnings) — recovery inflection confirmed; +20-25%
• ◆Major pharma or biotech signs BTS deal >100,000 SF (any quarter) — demand proof; +10-20%
• ◆Credit rating affirmed with stable outlook (H2 2026) — eliminates downgrade tail risk; +5-10%

• ◆Lab oversupply extends through 2028+ — HIGH severity, 25% probability
• ◆Second dividend cut if payout ratio exceeds 80% FFO — MEDIUM severity, 30% probability in 24 months
• ◆NIH cuts >20% sustained multi-year — HIGH severity, 10% probability
• ◆Credit rating downgrade BBB+ → BBB — MEDIUM severity, 20% probability
• ◆Structural wet lab demand decline from AI drug discovery — CRITICAL severity if confirmed, 5% probability
• ◆Disposition program achieves only $1.0-1.5B vs. $2.9B target — MEDIUM severity, 35% probability of partial completion
• ◆Equity issuance at distressed prices — HIGH severity if triggered, 10% probability